Meta-analysis of the safety of Yangzhengxiaoji capsule for the treatment of cancer and precancerosis
10.3969/j.issn.1000-8179.20131476
- VernacularTitle:养正消积胶囊应用于恶性肿瘤及癌前病变治疗中安全性的Meta分析
- Author:
Kan XUE
;
Fei SHAN
;
Jiafu JI
- Publication Type:Journal Article
- Keywords:
Yangzhengxiaoji capsule;
cancer;
precancerosis;
meta-analysis;
safety
- From:
Chinese Journal of Clinical Oncology
2013;(21):1318-1323
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety of Yangzhengxiaoji capsules for the treatment of cancer and precancerosis. Methods:Clinical trials and studies were collected by searching Chinese and English databases, including CNKI, WANFANG database, VIP information database, Pubmed, ScinenceDirect Online, and MEDLINE@EBSCO. The clinical data of Yangzhengxiaoji capsule for the treatment of cancer and pre-cancerosis were included. The quality of the included studies was then evaluated. Related data were extracted with reference to Cochrane Handbook 5.0. Afterward, meta-analysis was conducted using Revman 5.0 software. Results:A total of 19 studies focusing on 2 125 patients receiving Yangzhengxiaoji capsules were included and investigated in this meta-analysis. Results showed that the adverse reaction rates of myelosuppression, WBC and platelet decrease, gastrointestinal reaction, nausea/vomiting, and hepatotoxicity were sig-nificantly lower in the trial groups with Yangzhengxiaoji capsule-assisted chemotherapy/radiotherapy than in the control groups with chemotherapy/radiotherapy only (P<0.05). The adverse reaction rates of nephrotoxicity, cardiotoxicity, and neurotoxicity were not statistically different between the trial groups and the control groups (P>0.05). Conclusion:Yangzhengxiaoji capsule could be safely administered to treat cancer and precancerosis.
